OverviewSuggest Edit

Cryoport delivers a complete outsourced frozen shipping solution for biological materials. This combination replaces outdated dry ice shipping, virtually eliminates the risk of cell degradation and revolutionizes deep frozen logistics. We combine the technology of liquid nitrogen dry vapor shippers with the most advanced Logistics Management Platform in the industry. The Company provides a complete outsourced solution that advances deep-frozen shipping for the life science community.
TypePublic
Founded1990
HQIrvine, US
Websitecryoport.com

Latest Updates

Employees (est.) (Dec 2018)92(+62%)
Job Openings5
Revenue (FY, 2018)$19.6 M(+65%)
Share Price (Jun 2019)$18.5 (+6%)

Key People/Management at Cryoport

Jerrell W. Shelton

Jerrell W. Shelton

President and Chief Executive Officer
Robert Stefanovich

Robert Stefanovich

CFO
Bret Bollinger

Bret Bollinger

Vice President of Operations
Show more

Cryoport Office Locations

Cryoport has an office in Irvine
Irvine, US (HQ)
17305 Daimler St
Show all (1)

Cryoport Financials and Metrics

Cryoport Revenue

Embed Graph
View revenue for all periods
Cryoport's revenue was reported to be $19.63 m in FY, 2018
USD

Revenue (Q2, 2019)

8.5m

Gross profit (Q2, 2019)

4.3m

Gross profit margin (Q2, 2019), %

51.3%

Net income (Q2, 2019)

(2.5m)

EBIT (Q2, 2019)

(2.3m)

Market capitalization (10-Jun-2019)

564.6m

Closing stock price (10-Jun-2019)

18.5

Cash (30-Jun-2019)

80.6m
Cryoport's current market capitalization is $564.6 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

2.7m3.9m5.9m12.0m19.6m

Revenue growth, %

48%49%

Cost of goods sold

2.2m2.8m4.0m6.0m9.4m

Gross profit

437.0k1.2m1.9m6.0m10.2m
Quarterly
USDQ2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

579.8k936.6k825.0k975.2k1.4m1.4m1.5m1.9m2.0m2.7m2.9m3.0m4.0m4.6m5.3m6.7m8.5m

Cost of goods sold

507.7k597.2k600.0k740.7k943.2k1.0m1.1m1.1m1.2m1.5m1.5m1.4m1.8m2.1m2.5m3.2m4.1m

Gross profit

72.1k339.4k225.0k234.5k487.9k436.3k384.3k782.0k796.8k1.3m1.4m1.6m2.2m2.5m2.7m3.5m4.3m

Gross profit Margin, %

12%36%27%24%34%30%26%41%40%46%48%54%54%54%52%52%51%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

369.6k1.4m2.8m15.0m37.3m

Accounts Receivable

678.0m

Inventories

29.7k69.7k69.8k114.8k220.5k

Current Assets

1.1m2.2m4.1m17.3m51.8m
Quarterly
USDQ2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

532.5k170.5k103.3k773.9k2.4m7.1m5.2m4.5m2.6m14.5m12.9m15.4m19.0m20.0m13.8m32.8m80.6m

Accounts Receivable

4.2m6.1m

Inventories

43.3k38.6k58.8k67.0k104.8k79.2k52.9k83.5k82.2k71.0k72.6k90.3k121.9k97.3k130.3k227.1k306.4k

Current Assets

1.0m783.4k655.5k1.4m3.5m8.0m6.2m5.9m4.2m16.4m14.5m17.2m22.0m24.2m27.9m52.4m101.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(19.6m)(7.0m)(9.8m)(7.9m)(9.6m)

Depreciation and Amortization

311.6k197.9k239.2k664.8k857.9k

Inventories

9.5k(40.0k)(70.5k)(25.3k)(105.7k)

Accounts Payable

Quarterly
USDQ2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(16.3m)(2.3m)(3.7m)(1.4m)(1.9m)(4.3m)(7.1m)(3.9m)(6.1m)(1.8m)(3.6m)(5.6m)(2.7m)(5.2m)(7.3m)(2.4m)(4.9m)

Depreciation and Amortization

179.0k55.1k105.2k45.7k94.0k166.3k97.8k198.6k131.6k307.9k492.0k187.8k379.2k593.2k300.6k797.3k

Inventories

(4.1k)(8.9k)(29.1k)67.0k(35.1k)(41.6k)(15.3k)(13.7k)(12.4k)18.5k16.9k(755.0)(7.1k)17.5k(15.5k)(6.6k)(85.9k)

Accounts Payable

(221.5k)
USDY, 2019

Financial Leverage

1.2 x
Show all financial metrics

Cryoport Online and Social Media Presence

Embed Graph

Cryoport News and Updates

Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain

IRVINE, Calif., July 11, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) and EVERSANA™ have announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution. The alliance will be designed to leverage EVERSANA's position as...

Cryoport Announces Proposed Public Offering of Common Stock

IRVINE, Calif., June 19, 2019 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) (Nasdaq: CYRXW) ("Cryoport" or the "Company") today announced that it intends to offer shares of common stock in an underwritten public offering under an effective shelf registration statement on file with the...

Cryoport Expands into Biostorage through the Acquisition of Cryogene

IRVINE, Calif., May 14, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that it has expanded its suite of temperature-controlled solutions...

Cryoport Appoints Daniel M. Hancock to Board of Directors

IRVINE, Calif., Jan. 7, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, is pleased to announce the appointment of Daniel M. (Dan) Hancock to its Board of...

Cryoport Announces $25 Million Investment from Petrichor Healthcare Capital Management

IRVINE, Calif., Dec. 17, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced the closing of a $25 million investment from Petrichor...

Cryoport Revenue Grows 76% for Third Quarter 2018; 91% Growth in Biopharma

IRVINE, Calif., Nov. 8, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced financial results for the three- and nine-month...
Show more

Cryoport Blogs

Biostorage: A Critical Component of the Medical Research Development Process

The human genome and diseases interact in mysterious ways. Along with external factors, these interactions can affect who gets an illness, how serious it gets, at what rate, how the patient responds to treatments and the longer prognosis. 

When Failure Isn’t an Option, Trust the Supply Chain Partners with a Proven and Successful Track Record

The advances in cell and gene therapy over the last few years have been nothing less than remarkable. The amount of resources being poured into their development is reflected in the large number of new and existing companies aspiring to bring these therapies to market. These treatments, …

Scientific Innovation is Messy. Cryoport is The Reliable Logistics Provider for the Cell and Gene Therapy Trial Process

Working for a company that supports cell and gene therapy industry, it’s always exciting to see new treatments finally go to market. Drug companies spend years trying to clear their new medicines through clinical trials and government approvals, and sometimes they don’t make it. But we k…

Cell and Gene Therapy Success Depends on Mastering the New Needs of the Supply Chain: Dispatch from the Shanghai CAR-T Summit

Cryoport was honored to be invited to speak at the CAR-T Summit in Shanghai, which gathered the world’s foremost experts on cell and gene therapy. While all presenters highlighted topics that were important to the industry, the CEO round table discussion was particularly insightful into …

Growing with Our Clients: New Cryoport Innovations Help Support Commercial Gene Therapies and Nearly 400 Clinical Trials

We’re proud to support the first-ever commercial CART-T therapies, produced by our clients Kite (Gilead), Novartis, and bluebird bio. We're equally proud to support more than 380 clinical trials in the regenerative medicine field across the globe. 

With More Than 200 Cell and Gene INDs on File with FDA by 2020, Challenges Lie Ahead on Path to Approval

 “By 2025, we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year based on an assessment of the current pipeline and the clinical success rates of these products.” – Scott Gottlieb, Former FDA Commissioner 
Show more

Cryoport Frequently Asked Questions

  • When was Cryoport founded?

    Cryoport was founded in 1990.

  • Who are Cryoport key executives?

    Cryoport's key executives are Jerrell W. Shelton, Robert Stefanovich and Bret Bollinger.

  • How many employees does Cryoport have?

    Cryoport has 92 employees.

  • What is Cryoport revenue?

    Latest Cryoport annual revenue is $19.6 m.

  • What is Cryoport revenue per employee?

    Latest Cryoport revenue per employee is $213.3 k.

  • Who are Cryoport competitors?

    Competitors of Cryoport include Somerset Logistics, PeriShip and Sendle.

  • Where is Cryoport headquarters?

    Cryoport headquarters is located at 17305 Daimler St, Irvine.

  • Where are Cryoport offices?

    Cryoport has an office in Irvine.

  • How many offices does Cryoport have?

    Cryoport has 1 office.